Journals / Viral Hepatitis Journal / 2019 / Cilt: 25 - Sayı: 1

Non-hodgkin Lymphoma Developing After Discontinuation of Direct-acting Antiviral Treatment for Hepatitis C: A Case Report

Hepatit C’nin Direk Etkili Antivirallerle Tedavisinden Sonra Gelişen Non-hodking Lenfoma: Bir Olgu Sunumu

Pages
32–34
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper, we present the case of B-cell non-Hodgkin lymphoma developing after DAA treatment in a patient with complete response to hepatitis C treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Today, direct-acting antivirals (DAA) are the main treatment options for hepatitis C infection.
📊
Key Findings & Data:However, whether malignancy risk is increased after DAA treatment is a matter of debate.
💡
Conclusion & Impact:In this paper, we present the case of B-cell non-Hodgkin lymphoma developing after DAA treatment in a patient with complete response to hepatitis C treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Today, direct-acting antivirals (DAA) are the main treatment options for hepatitis C infection. However, whether malignancy risk is increased after DAA treatment is a matter of debate. Conflicting results have been reported in the relevant studies. In this paper, we present the case of B-cell non-Hodgkin lymphoma developing after DAA treatment in a patient with complete response to hepatitis C treatment.

Özet

Günümüzde doğrudan etkili antiviraller (DAA), hepatit C enfeksiyonu için ana tedavi seçenekleridir. Fakat DAA tedavilerinden sonra, hastalarda malignite riskinin arttığına yönelik olgu sunumları vardır. Konuyla ilgili araştırmalarda çelişkili sonuçlar bildirilmiştir. Bu sunumda DAA tedavisi sonrasında tam cevap elde edilen bir hastada tedaviden sonra gelişen B hücreli non-Hodgkin lenfoma ve arasındaki deneyimin paylaşılması amaçlanmıştır.

🔖

Cite This Article

KARABAY, O., GÜÇLÜ, E., KÖSEM, M., HACIBEKİROĞLU, T. (2022). Non-hodgkin Lymphoma Developing After Discontinuation of Direct-acting Antiviral Treatment for Hepatitis C: A Case Report. Viral Hepatitis Journal, Cilt: 25 - Sayı: 1, 32–34. https://ajindex.com/articles/646374

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Gupta V, Kumar A, Sharma P, Arora A. Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. Indian J Med Res. 2017;146:23-33
  2. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol. 2016;65:663-665
  3. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719-726
  4. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727-733
  5. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: [email protected]. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016;65:734740
  6. Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Teng HW, Wang WS, Chao TC, Yen CC, Chen PM. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma. Ann Hematol. 2008;87:475-480
  7. Khaled H, Abu-Taleb F, Haggag R. Hepatitis C virus and nonHodgkin’s lymphomas: A minireview. J Advanc Res. 2017;8:131137
  8. Vannata B, Arcaini L, Zucca E. Hepatitis C virus-associated B-cell non-Hodgkin’s lymphomas: what do we know? Ther Adv Hematol. 2016;7:94-107
  9. Kuo SH, Yeh KH, Chen LT, Lin CW, Hsu PN, Hsu C, Wu MS, Tzeng YS, Tsai HJ, Wang HP, Cheng AL. Helicobacter Pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity. Blood Cancer J. 2014;4:220
  10. Serti E, Park H, Keane M, O’Keefe AC, Rivera E, Liang TJ, Ghany M, Rehermann B. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα. Gut. 2017;66:724-735
  11. Chu PS, Nakamoto N, Taniki N, Ojiro K, Amiya T, Makita Y et al. On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. PLoS One. 2017 15;12:e0179096
  12. Makarova-Rusher OV, Med